Crohn’s disease is a form of chronic inflammatory bowel disease (IBD) that causes inflammation in the gastrointestinal tract. This inflammation can take place anywhere between the ileum of the small intestine to the colon of the large intestine. Common symptoms of Crohn’s disease from mild to severe intensity include abdominal pain, reduced appetite, fever, and frequent diarrhea. Rectal bleeding is encountered in few cases due to fissures from inflammation at anal canal. Factors responsible for causing Crohn’s disease include hereditary genes, autoimmune reaction that causes inflammatory condition, and environmental factors such as bacteria and virus. The disease majorly affects people falling between age group of 15-35 years and occurs in moth males and females.
Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/1237
The North America and Europe regions have high incidence of Crohn’s disease, which is expected to drive the growth of market. According to the journal of Gastroenterology’s on Inflammatory Bowel Disease (IBD) in 2017, around 1.6 million patient in the U.S were suffering from of IBD, out of which considerable section belongs to Crohn’s disease. Additionally, fast-track drug approval application of FDA pertaining to treatments for Crohn’s disease is also expected to foster the market in the forecast years. The pipeline drugs offering innovative treatment solutions expecting to receive marketing approvals are anticipated to propel the market growth. For instance, launch of interleukin (IL) inhibitor and anti-integrin therapy for Crohn’s disease, risankizumab, is in the Phase III clinical trials of FDA developed by AbbVie and is expected to complete its trials by January 2022. However, lack of awareness regarding available treatment options is expected to act as hindrance in the market growth.
Market players are engaged in innovative product launches to sustain their position in the global Crohn’s disease treatment market
Key players in the market are focused on expansion of their presence through launch of new drugs and treatment options worldwide. For instance, in September 2016, Janssen Biotech, Inc, received FDA approval for STELARA for the treatment of moderate to severe Crohn’s disease that have failed responding to the immunomodulators and corticosteroid treatments earlier. Moreover, application of fast-track approval programs by FDA pertaining to IBD treatments is also expected to provide opportunities to market players to capitalize upon and improve significance in the global Crohn’s disease market. The Center for Drug Evaluation and U.S. FDA released a new document named New Drug Therapy Approvals in 2017 that included fast-track drug and biosimilar approval clauses for Crohn’s disease and inflammatory bowel disease.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/1237
Key players operating the global Crohn’s disease treatment market include AbbVie Inc., Janssen Biotech, Inc., Allergan Inc., Bayer AG, Bristol-Myers Squibb, Pfizer, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.